HOT SUMMER IN DRUG SAFETY
DRUG SAFETY IN THE COVID ERA
Inaugural Online Summit
ISOP ISRAEL & MOTHERISK INTERNATIONAL
4:00pm IDT ( UTC+3)
During the Corona pandemic, many therapeutic assumptions have been made, driven by the urgency to treat severely affected patients. Some drugs were already well known for other indications, and some of them are new molecules.
There were numerous attempts to publish non-peered review articles to quickly share experiences among clinicians. However, this sense of urgency has brought hasty and contradictory results which have caused confusion and at time panic, when claims that the virus increases toxicity of certain drugs
CIOMS* has issued a statement stressing the importance of demonstrating the benefit-risk profile of hypothetical treatments by adhering to thorough science-based evaluation with clinical trials and epidemiologic studies. CIOMS issued also a new report on Drug-Induced Liver Injury, particularly relevant in our current situation.
This workshop will address these urgent issues, as well as medication errors, misuse, and miscommunication. We are proud to welcome our speakers who are renowned international experts.
CIOMS*: Council of International Organization of Medical Sciences, a WHO-UNESCO founded the organization, setting up, since 1949, the standards for international clinical, safety and quality regulations)
Review of safety issues of drugs used with COVID 19 patients, either to treat the infection, or drugs who may impact the severity of the infection
14:00-14:05 Opening words
Dr. Rina Irene Fermont, Chairman ISOP ISRAEL
14:05-14:20 From Our Guest lecturer from USA : The Battle Against COVID-19: Are we behind the Eight Ball?
Peter Pitts: president of CMPI Center for Medicine in Public Interest, past FDA Associate Commissioner
14:20-14:35 Key Note Lesson COVID 19 drugs in pregnancy
Prof. Gideon Koren, Paediatrician and pharmacologist, Founder of Motherisk International in Canada , Israel and many other countries, Ariel University
14:35:14:50 Program for fast track authorization of drugs used in COVID 19
Israel Ministry of Health
14:50-15:05 Drugs used regularly by patients which may affect the severity of COVID19 Infection
Dr. Lee Goldstein: president of the Israeli Clinical Pharmacology Association, Head of the pharmacology department at Afula Medical Center
15:05-15:20 The different approaches to validate the safety profile when repositioning a drug for a new indication;
Prof Gideon Koren
15:20-15: 35 Using Artificial Intelligence to detect adverse events
Dr Gidi Stein, CEO MedAware, AI solution to prevent medication errors
What you will learn?
Better evaluate the safety profile of drugs used in COVID patients
Understand how to validate assumptions when repositioning a drug in a new indication
How to avoid medications errors and ways to evaluate your practices
Ways to measure before and after implementing your safety measures
How to communicate with patients controversial, insufficiently proven medications